Abstracts Archive - Page 18 of 2616 - ACR Meeting Abstracts

Abstract Number: 0191 • ACR Convergence 2025
Advanced therapy use in RA patients with moderate disease activity in a large NHS Foundation Trust in South London, UK
Aoibhinn Kelly¹, Maddalena Rupnik², Nasra Ahmed¹, Mrinalini Dey³ and Elena Nikiphorou⁴, ¹King's College Hospital NHS Foundation Trust, London, United Kingdom, ²Faculty of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ³Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁴King's College London, London, United Kingdom
Background/Purpose: Moderate disease in rheumatoid arthritis (RA) is defined as a 28-joint disease activity score (DAS28) of 3.2-5.1(MDAS). As per the National Institute for Health…
Abstract Number: 0200 • ACR Convergence 2025
Severe infections and malignancies in patients with cranial and extracranial giant cell arteritis treated with tocilizumab. National multicenter study of 471 patients of clinical practice
Adrian Martin-Gutierrez¹, Javier Loricera², Vicente Aldasoro Cáceres³, Olga Maiz⁴, Eugenio de Miguel⁵, Eva Galíndez Agirregoikoa⁶, Ivan Ferraz Amaro⁷, Santos Castañeda⁸ and Ricardo Blanco⁹, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Hospital Universitario de Navarra, Pamplona, Spain, ⁴Hospital Universitario de Donosti, Donostia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Infections and malignancies are two of the most feared side effects of biologic therapies. Giant cell arteritis (GCA) is a vasculitis which affects older…
Abstract Number: 0154 • ACR Convergence 2025
Incidence and Prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-ILD) in the United States
Diana Martins¹, George Mu², Elaine Irving³, Roger A. Levy⁴, Nisha Bhatt⁵ and Keele E. Wurst⁶, ¹GSK, Epidemiology, Toronto, ON, Canada, ²GSK, Statistics, Collegeville, PA, ³GSK, Clinical, Stevenage, United Kingdom, ⁴GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁵GSK, Global Medical Affairs, Collegeville, PA, ⁶GSK, Immunology and Emerging Epidemiology, Durham, NC
Background/Purpose: Despite the high disease burden and reduced quality of life for patients with CTD-ILD, data on its incidence and prevalence – particularly by CTD…
Abstract Number: 0156 • ACR Convergence 2025
Heat Exposure and Acute Care Utilization among Individuals with Rheumatic Conditions: A Time Series Framework for Identifying Delayed Associations
Leah Santacroce¹, Jamie Collins¹, Ana Valle², Rebecca Summit³, Paul Dellaripa⁴ and Candace Feldman¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Brookline, MA, ³Brigham & Women's Hospital, Boston, MA, ⁴Brigham and Womens Hospital, Boston, MA
Background/Purpose: Temperature and air pollution are increasing each year across the US. There is growing interest in studying how the effects of high temperature impact…
Abstract Number: 0145 • ACR Convergence 2025
Population Assessment of Cancer Incidence among Patients with Idiopathic Inflammatory Myopathies in North Carolina
Astia Allenzara¹, Ben Albright², Xi Zhou², Amanda Nelson³, Laura Green⁴, Katherine Reeder-Hayes⁴, Jennifer Lund⁴, Caroline Thompson⁴ and Chris Baggett⁴, ¹UNC, Chapel Hill, NC, ²University of North Carolina, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴University of North Carolina, Chapel Hill
Background/Purpose: Cancer is highly prevalent and a leading cause of death for patients with Idiopathic Inflammatory Myopathies (IIM). Evaluating cancer type and stage at diagnosis…
Abstract Number: 0161 • ACR Convergence 2025
Risk Factors and Clinical Predictors of Lung Cancer in Systemic Sclerosis: A Matched Case-Control Study from a Michigan Cohort
Madiha Naqsh Siddiqui¹, Yen Chen¹, Rosemary Gedert², Suiyuan Huang², Dinesh Khanna² and John Varga², ¹University of Michigan, Ann Arbor, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Malignancies are one of the leading causes of non-systemic sclerosis-related mortality in patients with systemic sclerosis (SSc)1, with lung cancer being the most common…
Abstract Number: 0153 • ACR Convergence 2025
Patient Experience and Implementation of an Electronic Patient-Reported Outcome Measures (ePROM) System for Remote Monitoring in BIOBADASER
Isabel Castrejón Fernández¹, Lucia Otero², Antonio Mera-Valera³, Alicia Garcia⁴, Silvia Gomez-Sabater⁵, Raquel Martín-Domenech⁶, Jose Alvaro-Gracia⁷, Juan Camilo Sarmiento-Monroy⁸, Beatriz Ventosa² and Fernando Sánchez-Alonso⁹, ¹Department of Rheumatology. Hospital General Universitario Gregorio Marañon. IiSGM. Universidad Complutense Madrid, Madrid, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³H. Clínico Universitario de Santiago, Santiago de Compostela, ⁴Rheumatologist, La Laguna, Spain, ⁵Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ⁶H. Universitario de Elda, Elda, Spain, ⁷Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Department of Rheumatology, Hospital General Universitario Gregorio Marañón and Faculty of Medicine, Complutense University of Madrid, Madrid, Spain, ⁸Hospital Clínic Barcelona, Barcelona, Spain, ⁹Sociedad Española de Reumatología, Madrid, Spain
Background/Purpose: Patient-Reported Outcome Measures (PROMs) are integral to shared decision-making and quality improvement in rheumatology. They are recommended for monitoring treatment response, assessing quality of…
Abstract Number: 0146 • ACR Convergence 2025
Association between frailty and delirium and hospitalization outcomes among older adults with rheumatic diseases
Bhavik Bansal¹, Yehseo Jung², Abdulla Damluji³, Parag Goyal⁴ and Namrata Singh⁵, ¹UT Southwestern Medical Centre, Dallas, TX, ²University of Washington, Seattle, WA, ³Johns Hopkins, Baltimore, ⁴Weill Cornell, New York, ⁵University of Washington, Bellevue, WA
Background/Purpose: We investigated the association of frailty and delirium, both independently and in combination, with in-hospital mortality and non-routine discharge (i.e. when a patient is…
Abstract Number: 0127 • ACR Convergence 2025
Single-cell Profiling of Dermal Endothelial Cells Reveals Potential Cell-Cell Interactions in Patients with APS and a History of Cardiac Valve Disease
Wenying Liang¹, Qinmengge Li², Jacqueline Madison¹, Ran Jing¹, Emily Chong¹, Yiran Shen¹, Rachael Bogle³, Srilakshmi Yalavarthi¹, Cyrus Sarosh⁴, Ajay Tambralli¹, Yu (Ray) Zuo¹, Johann Gudjonsson¹, Hui Shi⁵, Pei-Suen Tsou¹, Alex Tsoi³ and Jason S. Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ypsilanti, MI, ³University of Michigan, Holland, OH, ⁴University of Michigan, Temperance, MI, ⁵Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: Some of the rarer manifestations of antiphospholipid syndrome (APS), such as cardiac valve disease, remain poorly understood at the molecular level. A previous study…
Abstract Number: 0139 • ACR Convergence 2025
When One Isn’t Enough: Does Adding IgM Worsen the Antiphospholipid Syndrome Phenotype?
Santiago Dans Caballero¹, Massimo Radin², Chary López pedrera³, MARIA ANGELES AGUIRRE ZAMORANO⁴, Christian Merlo-Ruiz⁵, Ismael Sanchez-Pareja⁴, Irene Cecchi⁶ and Savino Sciascia⁷, ¹Reina Sofia University Hospital, Lebrija, Andalucia, Spain, ²University of Turin, Turin, Turin, Italy, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁵Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁶University of Turin, Turin, Piemonte, Italy, ⁷University of Turin, Torino, Italy
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the persistent presence of antiphospholipid antibodies (aPL) along with clinical manifestations such as venous…
Abstract Number: 0150 • ACR Convergence 2025
Mortality in Anca-associated Vasculitis
Fabricio Benavides Villanueva¹, Vanesa Calvo-Río², Diana Prieto-Peña³, Monica Renuncio-García⁴, Adrian Martin-Gutierrez⁵, Amparo Sanchez-Lopez⁶, Claudia Poo-fernandez⁷, Clara Escagedo-Cagigas⁸, maria Rodríguez-Vidriales⁸ and Ricardo Blanco², ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ⁶Division of Dermatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁷Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁸Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), include Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). Mortality rates are scare,…
Abstract Number: 0168 • ACR Convergence 2025
Risk of hospitalization in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
QIANRU ZHANG¹, Ying Qi², Xiaosong Wang³, Gregory McDermott⁴, Sung Hae Chang⁵, Liya Sisay Getachew⁶, Mark Chaballa⁷, Vadim Khaychuk⁸, Misti Paudel⁹, Katherine Liao¹⁰ and Jeffrey Sparks⁶, ¹Brigham and Women’s Hospital/Beijing Tsinghua Changgung Hospital, Cambridge, MA, ²Brigham and Women’s Hospital, Boston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵Soonchunhyang University College of Medicine, Cheonan, MA, South Korea, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Bristol Myers Squibb, Pennington, NJ, ⁹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA
Background/Purpose: RA-associated lung disease (RA-LD), including RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR), is a serious extra-articular manifestation of RA that significantly contributes…
Abstract Number: 0131 • ACR Convergence 2025
Libman-Sacks Endocarditis in APS: A Case-Control Study of Clinical and Serologic Features
Kyla Rodgers¹, Cyrus Sarosh², Srilakshmi Yalavarthi³, Emily Becker⁴, Yiran Shen⁵, Kaitlyn Sabb⁴, Peter Hagan⁴, Ajay Tambralli⁵, Jacqueline Madison⁵, Yu (Ray) Zuo⁵ and Jason S. Knight⁵, ¹University of Michigan, Whitmore Lake, MI, ²University of Michigan, Temperance, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, ⁴University of Michigan, Ann Arbor, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Libman-Sacks endocarditis (LSE) is an inflammatory phenomenon, typically involving the mitral or aortic valve, that affects some patients with systemic lupus erythematosus (SLE) and/or…
Abstract Number: 0195 • ACR Convergence 2025
Utility of Repeat ANA Testing
Michael Luggen¹ and Sila Mateo Faxas², ¹University of Cincinnati College of Medicine, Cincinnati, OH, ²Good Samaritan Hospital, Cincinnati, OH
Background/Purpose: The ANA by immunofluorescence is a sensitive screening test for most systemic auto-immune rheumatic diseases (SARDs). A negative result is oftentimes sufficient to exclude…
Abstract Number: 0189 • ACR Convergence 2025
“Try it, you’ll love it”: Patterns of AI Scribes Use Among Rheumatologists
Megan Creasman¹, Jing Li², Augusto Garcia-Agundez³, gabriela Schmajuk⁴ and Jinoos Yazdany³, ¹UC San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, San Francisco, CA, ⁴University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Heavy documentation contributes to clinician workload and burnout. Rheumatology carries one of the highest documentation burdens among Internal Medicine (IM) subspecialties. While recent advances…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].